NEW YORK (GenomeWeb News) – Becton Dickinson yesterday filed a statement with the US Securities and Exchange Commission outlining its intention to purchase TriPath Imaging for approximately $350 million.
 
BD said it proposed to acquire approximately 93.5 percent of TriPath’s outstanding shares for $9.25 per share. BD and TriPath have been collaborating to identify cancer biomarkers since 2001, when BD acquired an approximately 6.5-percent equity stake in TriPath.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.